Adicet Bio, Inc. filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies. Its Form 8-K reports cover material events, financial results, clinical and regulatory updates for prula-cel and ADI-212, Nasdaq listing-rule matters, and capital-structure disclosures involving common stock and pre-funded warrants.
Proxy filings describe shareholder voting matters, board and governance procedures, executive compensation, equity-award disclosures, and proposals affecting the company’s certificate of incorporation and share structure. These documents connect Adicet’s cell-therapy pipeline with its public-company governance, equity compensation, and financing-related disclosure obligations.
Adicet Bio, Inc. reported that an affiliate of RA Capital restructured part of its position through an exchange. On April 27, 2026, RA Capital Healthcare Fund, L.P. entered into an Exchange Agreement to swap 250,000 shares of Adicet Bio common stock for a pre-funded warrant for up to 250,000 common shares at an exercise price of $0.0001 per share, for no additional consideration. Following the transactions, the Fund held 932,624 shares of common stock and 1,402,833 pre-funded warrant shares indirectly. The pre-funded warrant is exercisable immediately, has no expiration date, and includes a 9.99% beneficial ownership limit that prevents exercises above that level when combined with Attribution Parties.
Adicet Bio, Inc. is holding its 2026 annual stockholders meeting virtually on June 17, 2026 at 5:00 p.m. Eastern Time. Holders of common stock as of April 21, 2026, when 9,598,201 shares were outstanding, may vote online, by phone, mail or during the webcast using a 16‑digit control number.
Stockholders will vote on electing three Class II directors to terms ending in 2029, approving on a non‑binding advisory basis the compensation of named executive officers, and ratifying KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026. The proxy describes board structure, committee responsibilities, director and executive biographies, and outlines the company’s executive and director compensation programs, including cash retainers, equity awards, and 2025 bonus opportunities.
Adicet Bio, Inc. entered into an exchange agreement with RA Capital under which RA Capital swapped 250,000 shares of Adicet common stock for a pre-funded warrant to acquire 250,000 common shares.
The warrant carries a token exercise price of $0.0001 per share and is exercisable immediately via cashless exercise. It includes a 9.99% cap on both beneficial ownership and voting power, which can be increased on at least 61 days’ prior notice but not above 19.99%. The issuance relied on the Section 3(a)(9) exemption from Securities Act registration.
RA Capital Management, L.P. and affiliated reporting persons reported beneficial ownership of 1,182,624 shares of Adicet Bio, Inc. common stock. The filing states the Fund also holds pre-funded warrants exercisable for up to 1,152,833 additional shares, but a Beneficial Ownership Blocker prevents exercise that would raise ownership above 9.99%. The percentage reported (12.3%) is calculated using 9,596,407 shares outstanding as of March 10, 2026. The filing discloses delegated voting and dispositive authority to RA Capital and includes standard disclaimers regarding beneficial ownership for Section 13(d) purposes.
RA Capital–affiliated entities reported open-market purchases of Adicet Bio common stock. RA Capital Healthcare Fund LP, managed by RA Capital Management, L.P., bought 74,577 shares at $7.04 on February 18, 74,268 shares at $7.21 on February 19, and 74,751 shares at $7.27 on February 20. All shares are held directly by the Fund, with RA Capital and individuals Peter Kolchinsky and Rajeev Shah disclaiming beneficial ownership beyond their pecuniary interests. After the latest trade, the indirect holdings reported for the Fund total 1,182,624 shares, and no derivative securities are listed.
Adicet Bio, Inc. received an initial ownership report from RA Capital–related entities, which are ten percent owners. The filing lists indirect holdings of a Pre-Funded Warrant exercisable into 1,152,833 shares of common stock at an exercise price of $0.0001 per share, plus 959,028 shares of common stock held indirectly.
The Pre-Funded Warrants are exercisable immediately and have no expiration date, but contain a 9.99% beneficial ownership cap that prevents exercises taking the group above that level. RA Capital Management, its general partner, the Fund, and Dr. Peter Kolchinsky and Mr. Rajeev Shah each disclaim beneficial ownership beyond their pecuniary interest.
OrbiMed-affiliated funds reduced their stake in Adicet Bio, Inc. common stock and filed Amendment No. 9 to Schedule 13D. The reporting group, led by OrbiMed Advisors LLC, now may be deemed to beneficially own 844,787 Shares, representing 8.8% of Adicet Bio’s 9,596,407 Shares outstanding as stated in the company’s Form 10-K.
OrbiMed Private Investments V, LP holds 564,147 Shares (5.9%), and OrbiMed Private Investments VI, LP holds 280,640 Shares (2.9%). Other OrbiMed-related vehicles, including OrbiMed Genesis Master Fund, OrbiMed Israel Partners and OrbiMed Israel Partners II, report holding 0 Shares.
The amendment was triggered after open-market sales described in Item 5(c), including April 7–8, 2026 transactions by OrbiMed Israel Partners and OrbiMed Israel Partners II and an April 9, 2025 sale by OrbiMed Genesis at per-share prices in the mid-$6 range.
Adicet Bio shareholder update: Investment entities affiliated with OrbiMed reported open-market sales of a total of 104,658 shares of Adicet Bio common stock on April 7–8, 2026, at prices between about $6.29 and $6.53 per share. The Form 4 shows these OrbiMed-related funds continuing to hold sizable indirect positions, including 564,147 shares, 280,640 shares, and 78,499 shares of Adicet Bio common stock through various limited partnerships.